View Our Clinical Trials

office@woendo.com

(407) 480-4830

1510 Citrus Medical Ct
Ocoee, FL 34761

Clinical Trials

What are clinical trials?

Participating in a clinical trial is not just contributing to research — it’s a proactive healthcare choice. Clinical trials offer access to advanced medical care, often including more frequent monitoring, extra diagnostic testing, and expert oversight from specialized healthcare teams. Participants may receive investigational treatments that have shown promising results and are not yet available to the general public. These therapies often represent the latest innovations in medicine, offering hope and potential benefits beyond current standard care.

In addition to the potential personal health benefits, participants are often compensated for their time and travel, making involvement more accessible. Most importantly, by joining a clinical trial, you’re playing a vital role in the advancement of science and helping shape the future of medicine — paving the way for better treatments for yourself and others.

Why Consider Participating in a Clinical Trial?

Care at No Cost
Our clinical trials provide qualifying participants with high-quality medical care at no charge. This includes regular health checkups, specialized testing, and ongoing monitoring — services that may otherwise be costly or difficult to access.

Access to Cutting-Edge Treatments
Participants may gain early access to innovative treatments and medications that are not yet widely available but have shown promising results in previous studies. These investigational therapies represent the forefront of medical advancement — and are offered at no cost to eligible participants.

Compensation and Support
In most studies, participants are compensated for their time, travel, and participation. While treatments are provided free of charge, this additional support helps offset the personal investment of being part of a trial.

Make a Meaningful Impact
By joining a clinical trial, you’re not only exploring a new care option for yourself — you’re helping advance medical research and contributing to discoveries that could improve or save lives in the future.

Gain Insight and Empowerment
Participation often includes enhanced health monitoring, which can give you a deeper understanding of your condition. This added knowledge can empower you to take control of your health with greater confidence and clarity.

Work with Leading Specialists
Our trials are conducted by experienced medical professionals and research teams dedicated to the highest standards of care. You’ll be in the hands of experts who are passionate about advancing medicine and supporting your journey.

Current Areas of Disease Research :

  • Type 1 Diabetes
  • Type 2 Diabetes & Obesity
  • Obesity
  • Chronic Kidney Disease
  • Hypothyroidism

 

Active – Recruiting:

Zupreme 2 / ZP8396-24115

  • Condition: Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
  • Status: Active – Recruiting
  • Sponsor: Zealand Pharma
  • Type of Study: Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
  • Study Length: 28 Weeks
  • Target Age/Sex: ≥18
  • Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
  • To check eligibility criteria please visit: https://classic.clinicaltrials.gov/ct2/show/NCT04419779 
  • To fill out a pre-screening survey please visit: https://www.woendo.com/research-screening/

GZPO

ReCET / 898

  • Condition: Type II Diabetes
  • Status: Active – Recruiting
  • Sponsor: Endogenex
  • Type of Study: A Multicenter, Randomized, Double-blind, Sham-controlled study for Assessing the Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals with Type II Diabetes.
  • Study Length: 52 Weeks
  • Target Age/Sex: 18 Years to 70 Years   (Adult, Older Adult)
  • Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
  • Check Procedure Video: https://www.endogenex.com/recet/
  • To check eligibility criteria please visit: https://clinicaltrials.gov/study/NCT06267391
  • To fill out a pre-screening survey please visit: https://www.woendo.com/research-screening/

BaxDuo Pacific / D6972C00002

  • Condition: Chronic Kidney Disease with Proteinuria
  • Status: Active – Recruiting
  • Sponsor: AstraZeneca
  • Type of Study: A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin in Participants with Chronic Kidney Disease and High Blood Pressure – BaxDuo-Pacific
  • Study Length: 24-months
  • Target Age/Sex:18 Years to 130 Years (Adult, Older Adult)
  • Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
  • To check eligibility criteria please visit: https://classic.clinicaltrials.gov/ct2/show/NCT04419779 
  • To fill out a pre-screening survey please visit: https://www.woendo.com/research-screening/

BaxDuo Artic / D6972C00003

  • Condition: Chronic Kidney Disease with Proteinuria
  • Status: Active – Recruiting
  • Sponsor: AstraZeneca
  • Type of Study: A Phase III, Randomised, Double-Blind, Active-controlled Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on Chronic Kidney Disease (CKD) Progression in Participants With CKD and High Blood Pressure
  • Study Length: 24-months
  • Target Age/Sex:18 Years to 130 Years (Adult, Older Adult)
  • Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
  • To check eligibility criteria please visit: https://classic.clinicaltrials.gov/ct2/show/NCT04419779 
  • To fill out a pre-screening survey please visit: https://www.woendo.com/research-screening/

Solstice / D761C00001

  • Condition: Type II Diabetes
  • Status: Active – Recruiting
  • Sponsor: AstraZeneca
  • Type of Study: Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 versus Placebo for 26 Weeks in Adults with Type 2 Diabetes Mellitus.
  • Study Length: 26 Weeks
  • Target Age/Sex: ≥18
  • Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
  • To check eligibility criteria please visit: https://clinicaltrials.gov/study/NCT06267391
  • To fill out a pre-screening survey please visit: https://www.woendo.com/research-screening/

Avanti / M21-341

    • Condition: Hypothyroidism
    • Status: Active – Recruiting
    • Sponsor: AbbVie
    • Type of Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism
    • Study Length: 81 Weeks
    • Target Age/Sex: 18 Years to 75 Years   (Adult, Older Adult)
    • Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
    • To check eligibility criteria please visit: https://classic.clinicaltrials.gov/ct2/show/NCT06345339
    • To fill out a pre-screening survey please visit: https://www.woendo.com/research-screening/

_____________________________________________________________________________________________

Closed Enrollment & Completed Trials:

1.NCT Number: NCT00698230. Study Name: . Sponsor: Incyte Corporation. Role: Sub- Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2008. Completed Date: 2009.

2.NCT Number: NCT00707993. Study Name: . Sponsor: Takeda. Role: Sub- Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2008. Completed Date: 2010.

3.NCT Number:  NCT00751842. Study Name: DIAPREVENT. Sponsor: Diamyd Therapeutics AB. Role: Sub- Investigator. Condition I: Type I Diabetes Mellitus. Start date: 2012. Completed Date: 2012.

4.NCT Number: NCT01989754. Study Name: CANVAS. Sponsor: Janssen Research & Development, LLC. Role: Sub- Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2014. Completed Date: 2017.

5.NCT Number: NCT00789737. Study Name: . Sponsor: Daiichi Sankyo, Inc. Role: Sub- Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2009. Completed Date: 2011.

6.NCT Number: NCT01018173. Study Name: . Sponsor: Roche. Role: Sub- Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2010. Completed Date: 2011.

7.NCT Number: NCT01499082. Study Name: Edition I. Sponsor: Sanofi. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2016. Completed Date: 2018.

8.NCT Number: NCT02855684. Study Name: Edition AP. Sponsor: Sanofi. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2016. Completed Date: 2018.

9.NCT Number: NCT01995734. Study Name: ACCESS. Sponsor: Novartis Pharmaceuticals. Role: Principal Investigator. Condition I: Acromegaly. Start date: 2013. Completed Date: 2015.

10.NCT Number: NCT02058147. Study Name: . Sponsor: Sanofi. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2014. Completed Date: 2015.

11.NCT Number:  NCT02058147. Study Name: . Sponsor: Sanofi. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2014. Completed Date: 2015.

12.NCT Number: NCT02320721. Study Name: SENIOR. Sponsor: Sanofi. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2015. Completed Date: 2016.

13.NCT Number: NCT02294474. Study Name: SORELLA2. Sponsor: Sanofi. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2015. Completed Date: 2016.

14.NCT Number: NCT02967224. Study Name: (Reach-Control). Sponsor: Sanofi. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2015. Completed Date: 2017.

15.NCT Number: NCT02642159. Study Name: ODYSSEY DM-Dyslipidemia. Sponsor: Sanofi. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2016. Completed Date: 2017.

16.NCT Number: NCT02738151. Study Name: BRIGHT. Sponsor: Sanofi. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2016. Completed Date: 2017.

17.NCT Number: NCT02688933. Study Name: . Sponsor: Sanofi. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2016. Completed Date: 2017.

18.NCT Number: NCT03211858. Study Name: GEMELLI1. Sponsor: Sanofi. Role: Principal Investigator. Condition I: Type I Diabetes Mellitus. Start date: 2019. Completed Date: 2019.

19.NCT Number: NCT03066830. Study Name: SOTA-SU. Sponsor: Lexicon Pharmaceuticals. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2017. Completed Date: 2019.

20.NCT Number: NCT03242018. Study Name: SOTA-CKD4. Sponsor: Lexicon Pharmaceuticals. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2017. Completed Date: 2019.

21.NCT Number: NCT03242252. Study Name: SOTA-CKD3. Sponsor: Lexicon Pharmaceuticals. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2017. Completed Date: 2019.

22.NCT Number: NCT03332771. Study Name: SOTA-GLIM. Sponsor: Lexicon Pharmaceuticals. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2017. Completed Date: 2019.

23.NCT Number: NCT03449199. Study Name: . Sponsor: Teijin America, Inc. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2018. Completed Date: 2019.

24.NCT Number: NCT03518034. Study Name: TRAVERSE. Sponsor: AbbVie. Role: Principal Investigator. Condition I: Hypogonadism. Start date: 2018. Completed Date: 2023.

25.NCT Number: NCT03351478. Study Name: SOTA-EMPA. Sponsor: Lexicon Pharmaceuticals. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2017. Completed Date: 2019.

26.NCT Number: NCT02092467. Study Name: . Sponsor: Pfizer. Role: Principal Investigator. Condition I: RHEUMATOID ARTHRITIS. Start date: 2014. Completed Date: 2020.

27.NCT Number: NCT03285594. Study Name: SOTA-INS. Sponsor: Lexicon Pharmaceuticals/ Sanofi. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2017. Completed Date: 2019.

28.NCT Number: NCT03767543. Study Name: DIVERSITY. Sponsor: Sanofi. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2019. Completed Date: 2020.

29.NCT Number: NCT03874715. Study Name: GEMELLI X. Sponsor: Sanofi. Role: Principal Investigator. Condition I: Type I Diabetes Mellitus. Start date: 2019. Completed Date: 2020.

30.NCT Number:  NCT03895203. Study Name: BE OPTIMAL. Sponsor: UCB Biopharma SRL. Role: Principal Investigator. Condition I: Psoriatic Arthritis. Start date: 2019. Completed Date: 2022.

31.NCT Number: NCT03071692. Study Name: PROMINENT. Sponsor: Kowa Research Institute, Inc. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2017. Completed Date: 2022.

32.NCT Number: NCT03990363. Study Name: SAPPHIRE. Sponsor: AstraZeneca. Role: Principal Investigator. Condition I: Chronic Kidney Disease. Start date: 2019. Completed Date: 2022.

33.NCT Number: NCT04064411. Study Name: The wearABLe Study. Sponsor: Radius Health, Inc. Role: Principal Investigator. Condition I: Osteoporosis. Start date: 2019. Completed Date: 2021.

34.NCT Number: NCT04274894. Study Name: . Sponsor: AbbVie. Role: Principal Investigator. Condition I: Hypogonadism. Start date: 2020. Completed Date: 2021.

35.NCT Number: NCT04854512. Study Name: DREAM-T2D. Sponsor: Anji Pharma. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2018. Completed Date: 2023.

36.NCT Number: NCT04419467. Study Name: . Sponsor: CSL Behring. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2020. Completed Date: 2022.

37.NCT Number: NCT04657003. Study Name: SURMOUNT-2. Sponsor: Eli Lilly and Company. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2021. Completed Date: 2023.

38.NCT Number: NCT05182840. Study Name: MANOUVER. Sponsor: Boehringer Ingelheim. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2022. Completed Date:

39.NCT Number: NCT05056727. Study Name: STABILIZE. Official Title: A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia (STABILIZE-CKD). Sponsor: AstraZeneca. Role: Principal Investigator. Condition I: Renal Insufficiency. Start date:  2021. Completed Date: Closed.

40.NCT Number: NCT05275400. Study Name: QWINT-3. Official Title: A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (QWINT-3). Sponsor: Eli Lilly and Company. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2022. Completed Date: On-Going.

41.NCT Number: NCT05803421. Study Name: ACHIEVE-4. Official Title: A Phase 3, Open-Label Study of Once Daily LY3502970 Compared With Insulin Glargine in Adult Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk. Sponsor: Eli Lilly and Company. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2023. Completed Date: On-Going.

42.NCT Number: NCT05971940. Study Name: ACHIEVE-1. Official Title: A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone. Sponsor: Eli Lilly and Company. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2023. Completed Date: On-Going.

43.NCT Number: NCT06045221. Study Name: ACHIEVE-3. Official Title: A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared With Oral Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-3). Sponsor: Eli Lilly and Company. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2023. Completed Date: On-Going.

44.NCT Number: NCT04419779. Study Name: REVITALIZE 1. Official Title: A Prospective, Randomized, Double-Blind, Sham-Controlled, Multi-Center Pivotal Study to Evaluate the Efficacy and Safety of Duodenal Mucosal Resurfacing Using the Revita® System in Subjects With Type 2 Diabetes on Insulin Therapy. Sponsor: Fractyl Laboratories, Inc. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2021. Completed Date: On-Going.

45.NCT Number: NCT06065540. Study Name: REIMAGINE 2. Official Title: A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor (REIMAGINE 2). Sponsor: Novo Nordisk A/S. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2023. Completed Date: On-Going.

46.NCT Number: NCT05254002. Study Name: CONFIDENCE. Official Title: A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes (CONFIDENCE). Sponsor: Bayer. Role: Principal Investigator. Condition I: Chronic Kidney Disease. Start date: 2022. Completed Date: On-Going.

47.NCT Number: NCT06066515. Study Name: SYNCHRONIZE™-1 . Official Title: A Phase 3, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity Without Type 2 Diabetes. Sponsor: Boehringer Ingelheim. Role: Principal Investigator. Condition I: Overweight or Obesity. Start date: 2023. Completed Date: On-Going.

48.NCT Number: NCT06066528. Study Name: SYNCHRONIZE™-2 . Official Title: A Phase 3, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity and Type 2 Diabetes Mellitus. Sponsor: Boehringer Ingelheim. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2023. Completed Date: On-Going.

49.NCT Number: NCT06221969. Study Name: REIMAGINE 4. Official Title: A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor. Sponsor: NovoNordisk. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2024. Completed Date: On-Going.

50.NCT Number: NCT06534411. Study Name: REIMAGINE 5. Official Title: Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Sponsor: NovoNordisk. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2024. Completed Date: On-Going.